Chardan Capital Issues Positive Forecast for Krystal Biotech (NASDAQ:KRYS) Stock Price

Krystal Biotech (NASDAQ:KRYS) had its price objective upped by Chardan Capital from $220.00 to $323.00 in a research report report published on Wednesday morning, MarketBeat.com reports. Chardan Capital currently has a buy rating on the stock.

Several other analysts have also recently issued reports on KRYS. The Goldman Sachs Group increased their price target on shares of Krystal Biotech from $206.00 to $327.00 and gave the stock a “buy” rating in a research report on Friday, January 30th. Bank of America increased their target price on shares of Krystal Biotech from $288.00 to $318.00 and gave the stock a “buy” rating in a report on Thursday, January 22nd. TD Cowen restated a “buy” rating on shares of Krystal Biotech in a research note on Friday, January 9th. Zacks Research cut Krystal Biotech from a “strong-buy” rating to a “hold” rating in a research note on Thursday, February 5th. Finally, Weiss Ratings reiterated a “hold (c+)” rating on shares of Krystal Biotech in a report on Monday, December 29th. Nine analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $307.22.

Krystal Biotech Stock Down 1.6%

NASDAQ KRYS opened at $283.29 on Wednesday. The business’s fifty day simple moving average is $264.84 and its 200-day simple moving average is $208.40. The firm has a market cap of $8.22 billion, a PE ratio of 41.36 and a beta of 0.49. Krystal Biotech has a 52 week low of $122.80 and a 52 week high of $298.30.

Krystal Biotech (NASDAQ:KRYS) last issued its quarterly earnings data on Tuesday, February 17th. The company reported $1.70 earnings per share for the quarter, topping the consensus estimate of $1.62 by $0.08. The company had revenue of $107.11 million during the quarter, compared to analyst estimates of $105.30 million. Krystal Biotech had a return on equity of 18.69% and a net margin of 52.64%. Research analysts expect that Krystal Biotech will post 6.14 EPS for the current year.

Insider Activity

In related news, insider Suma Krishnan sold 25,000 shares of the stock in a transaction dated Thursday, December 4th. The shares were sold at an average price of $220.16, for a total transaction of $5,504,000.00. Following the completion of the transaction, the insider directly owned 1,413,711 shares of the company’s stock, valued at $311,242,613.76. This represents a 1.74% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, CAO Kathryn Romano sold 12,500 shares of Krystal Biotech stock in a transaction that occurred on Monday, February 9th. The shares were sold at an average price of $272.14, for a total value of $3,401,750.00. Following the completion of the sale, the chief accounting officer owned 19,318 shares in the company, valued at approximately $5,257,200.52. This trade represents a 39.29% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 13.70% of the stock is currently owned by corporate insiders.

Institutional Trading of Krystal Biotech

A number of institutional investors have recently bought and sold shares of the company. Hantz Financial Services Inc. raised its holdings in shares of Krystal Biotech by 8,950.0% in the second quarter. Hantz Financial Services Inc. now owns 181 shares of the company’s stock worth $25,000 after acquiring an additional 179 shares during the last quarter. Bessemer Group Inc. increased its position in Krystal Biotech by 106.9% during the 3rd quarter. Bessemer Group Inc. now owns 149 shares of the company’s stock worth $26,000 after purchasing an additional 77 shares in the last quarter. AdvisorNet Financial Inc purchased a new position in Krystal Biotech in the 3rd quarter valued at about $30,000. Salomon & Ludwin LLC acquired a new stake in shares of Krystal Biotech during the 3rd quarter worth about $33,000. Finally, First Horizon Advisors Inc. grew its holdings in shares of Krystal Biotech by 212.8% during the second quarter. First Horizon Advisors Inc. now owns 244 shares of the company’s stock worth $34,000 after buying an additional 166 shares in the last quarter. 86.29% of the stock is currently owned by hedge funds and other institutional investors.

Trending Headlines about Krystal Biotech

Here are the key news stories impacting Krystal Biotech this week:

• Positive Sentiment: Q4 beat: Krystal reported $1.70 EPS (vs. $1.62 est.) and $107.1M in VYJUVEK Q4 revenue with 94% gross margin — evidence of profitable commercial traction and stronger net income. Read More.
• Positive Sentiment: Regulatory/designation wins: FDA granted RMAT for KB707 (advanced NSCLC) and Fast Track for KB111 (Hailey‑Hailey disease) — these expedite development and add optionality beyond VYJUVEK. Read More.
• Positive Sentiment: Commercial progress: Over ~660 U.S. reimbursements for VYJUVEK and growing uptake in Germany, France and Japan (90+ patients prescribed across those markets). The company reiterated expansion plans and a strong cash position (~$956M). Read More.
• Positive Sentiment: Analyst uplift: Chardan raised its price target to $323 and reiterated a Buy, adding upward analyst momentum and supporting valuation narratives. Read More.
• Neutral Sentiment: Conference materials and transcripts: The Q4 earnings call transcript, slide deck and investor webcast are available for detailed read‑throughs (helpful for assessing management commentary on growth drivers and expenses). Read More.
• Negative Sentiment: Mixed market reaction / share weakness: Multiple outlets reported KRYS shares slipped (>2%) despite the earnings beat — suggests profit‑taking and short‑term volatility after the print. Read More.
• Negative Sentiment: Reimbursement & launch timing risk in Europe: Pricing negotiations in Germany and France could push meaningful EU revenue later into 2H‑2026/2027, adding execution risk to international growth. Read More.
• Negative Sentiment: Expense / guidance transparency concerns: SG&A rose materially year‑over‑year and management provided non‑GAAP combined R&D+SG&A guidance that excludes stock‑based comp (company says it cannot reliably reconcile)—this can create uncertainty around forward GAAP profitability. Read More.
• Negative Sentiment: Insider selling: Data show material insider sales activity over recent months, which can weigh on investor sentiment even as institutions adjust positions. Read More.

About Krystal Biotech

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.